Please Wait
Applying Filters...
menu
    • menu
    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    Kikkoman Biochemifa Company advances global health and safety through precision-driven innovation in biotech and food testing.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    Moehs Group, a reference company in the production of pharmaceutical active ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-10-20

    Virtual Booth

    An Enquiry

    Menu

    Evobrutinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: 1415823-73-2, 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one, Evobrutinib [inn], Msc2364447c, M-2951, Msc-2364447c
    Molecular Formula
    C25H27N5O2
    Molecular Weight
    429.5  g/mol
    InChI Key
    QUIWHXQETADMGN-UHFFFAOYSA-N
    FDA UNII
    ZA45457L1K
    Evobrutinib is an inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, evobrutinib inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways, which leads to the inhibition of the growth of malignant B-cells that overexpress BTK. BTK, a member of the Src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B-lymphocyte development, activation, signaling, proliferation and survival.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    1-[4-[[[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino]methyl]piperidin-1-yl]prop-2-en-1-one
    2.1.2 InChI
    InChI=1S/C25H27N5O2/c1-2-22(31)30-14-12-18(13-15-30)16-27-25-23(24(26)28-17-29-25)19-8-10-21(11-9-19)32-20-6-4-3-5-7-20/h2-11,17-18H,1,12-16H2,(H3,26,27,28,29)
    2.1.3 InChI Key
    QUIWHXQETADMGN-UHFFFAOYSA-N
    2.1.4 Canonical SMILES
    C=CC(=O)N1CCC(CC1)CNC2=NC=NC(=C2C3=CC=C(C=C3)OC4=CC=CC=C4)N
    2.2 Other Identifiers
    2.2.1 UNII
    ZA45457L1K
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. 1-(4-(((6-amino-5-(4-phenoxyphenyl)-4-pyrimidinyl)amino)methyl)-1-piperidinyl)-2-propen-1-one

    2. 2-propen-1-one, 1-(4-(((6-amino-5-(4-phenoxyphenyl)-4-pyrimidinyl)amino)methyl)-1-piperidinyl)-

    2.3.2 Depositor-Supplied Synonyms

    1. 1415823-73-2

    2. 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)piperidin-1-yl)prop-2-en-1-one

    3. Evobrutinib [inn]

    4. Msc2364447c

    5. M-2951

    6. Msc-2364447c

    7. Za45457l1k

    8. M2951

    9. 1-[4-[[[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino]methyl]piperidin-1-yl]prop-2-en-1-one

    10. 1-(4-((6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino)-methyl)-piperidin-1-yl)-propenone

    11. 2-propen-1-one, 1-(4-(((6-amino-5-(4-phenoxyphenyl)-4-pyrimidinyl)amino)methyl)-1-piperidinyl)-

    12. 1-(4-(((6-amino-5-(4-phenoxyphenyl)-4-pyrimidinyl)amino)methyl)-1-piperidinyl)-2-propen-1-one

    13. 1-[4-({[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino}methyl)piperidin-1-yl]prop-2-en-1-one

    14. 1-[4-[[[6-amino-5-(4-phenoxyphenyl)-4-pyrimidinyl]amino]methyl]-1-piperidinyl]-2-propen-1-one

    15. M-2951; Evobrutinib

    16. Evobrutinib [who-dd]

    17. Unii-za45457l1k

    18. Gtpl9752

    19. Chembl4072833

    20. Schembl14165673

    21. Bdbm291522

    22. Us9580449, Example A39

    23. Bcp28995

    24. Ex-a2691

    25. Us9580449, Example A250

    26. Nsc800892

    27. S8777

    28. Zinc205623965

    29. Ab90800

    30. Cs-6303

    31. Db15170

    32. Nsc-800892

    33. Msc 2364447

    34. Ac-35533

    35. Bs-15355

    36. Db-126809

    37. Hy-101215

    38. A16824

    39. D71175

    40. A902526

    41. A250 [wo2012170976]

    42. Q27295200

    43. M-2951; M 2951; M2951; Msc-2364447c; Msc 2364447c; Msc2364447c

    44. N-[(1-acryloylpiperidin-4-yl)methyl]-5-(4-phenoxyphenyl)pyrimidine-4,6-diamine

    2.4 Create Date
    2013-06-10
    3 Chemical and Physical Properties
    Molecular Weight 429.5 g/mol
    Molecular Formula C25H27N5O2
    XLogP34.2
    Hydrogen Bond Donor Count2
    Hydrogen Bond Acceptor Count6
    Rotatable Bond Count7
    Exact Mass429.21647512 g/mol
    Monoisotopic Mass429.21647512 g/mol
    Topological Polar Surface Area93.4 Ų
    Heavy Atom Count32
    Formal Charge0
    Complexity595
    Isotope Atom Count0
    Defined Atom Stereocenter Count0
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Drug and Medication Information
    4.1 Drug Indication

    Treatment of multiple sclerosis